Why the study?
Do DOACs reduce VTE recurrence, major bleeding, and mortality compared to other anticoagulants in patients with cancer-associated thrombosis?
Do DOACs reduce VTE recurrence, major bleeding, and mortality compared to other anticoagulants in patients with cancer-associated thrombosis?
In real-world clinical settings, DOACs are associated with improved efficacy and safety outcomes (lower VTE recurrence, major bleeding, and mortality) in patients with cancer-associated thrombosis.
May support DOAC preference in cancer-associated thrombosis; leaves open need for randomized confirmation.
In this comparative effectiveness study of claims-based data, patients with CAT received anticoagulation for a remarkably short duration in clinical settings. DOACs was associated with a lower risk of VTE recurrence, major bleeding, and mortality. Warfarin may still be considered for patients with contraindications to DOACs and those with poor persistence on LMWH.
No takes yet. Share an insight, caveat, or question.
Riaz et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: